1 September 2019 in Cardiovascular Pathology
1 August 2021 in Experimental and Clinical Psychopharmacology
Substance use disorder (SUD) is a behavioral disorder characterized by volitional drug consumption. Mouse models of SUD allow for the use of molecular, genetic, and circuit-level tools, providing enormous potential for defining the underlying mechanisms of this disorder. However, the relevance of results depends on the validity of the mouse models used. Self-administration models have long been the preferred preclinical model for SUD as they allow for volitional drug consumption, thus providing strong face validity. While previous work has defined the parameters that influence intravenous cocaine self-administration in other species-such as rats and primates-many of these parameters have not been explicitly assessed in mice. In a series of experiments, we showed that commonly used mouse models of self-administration, where behavior is maintained on a fixed-ratio schedule of reinforcement, show similar levels of responding in the presence and absence of drug delivery-demonstrating that it is impossible to determine when drug consumption is and is not volitional. To address these issues, we have developed a novel mouse self-administration procedure where animals do not need to be pretrained on sucrose and behavior is maintained on a variable-ratio schedule of reinforcement. This procedure increases rates of reinforcement behavior, increases levels of drug intake, and results in clearer delineation between drug-reinforced and saline conditions. Together, these data highlight a major issue with fixed-ratio models in mice that complicates subsequent analysis and provide a simple approach to minimize these confounds with variable-ratio schedules of reinforcement.
1 July 2026 in JCO Oncology Advances
PURPOSE: Reproductive care—including discussions about cancer-related infertility risk—is part of the recommended standard of care for all patients with cancer. Despite rising cancer incidence among adults younger than 50 years (early-onset), the evaluation of patients' knowledge about cancer-related infertility risk is limited. We characterized factors associated with lack of awareness of potential cancer-related infertility risk as reported by patients with early-onset cancer. PATIENTS AND METHODS: Using data from the Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study, we identified individuals diagnosed with a first primary early-onset cancer between 2006 and 2021. Awareness of potential cancer-related infertility risk was determined using questionnaires. Logistic regression models were fitted to examine associations between a lack of awareness of cancer-related infertility risk and patient-level factors. RESULTS: Among 636 patients, 28.9% (n = 184) reported never being told that their cancer treatments may affect their fertility. Patients who were aware of a potential cancer-related infertility risk had heard this information, on average, from two unique sources (mean = 2.2, std = 1.3)—with 90.1% of all sources derived from clinical interactions/settings. Patients who self-identified with a racial ethnic minority (REM) population—inclusive of African American/Black, American Indian, Asian, Hispanic/Spanish/Latino/a/x, Middle Eastern or North African, or multiple races—were nearly twice as likely to report an unawareness of infertility risk compared with patients who identified as non-Hispanic White after adjusting for diagnosis age and year, sex, insurance coverage, marital status, and pregnancy history (odds ratio, 1.70 [95% CI, 1.05 to 2.74]; P = .03). CONCLUSION: Three in every 10 patients with early-onset cancer reported never having been told that cancer treatments may affect their fertility. Individual factors contributed to differences in patients' knowledge of potential cancer-related infertility risk. Further study is needed to address this care gap among patients and providers to deliver concordant, high-quality reproductive and oncology care to this growing population.